Dr. Irene Ghobrial, MD, clinical investigator and senior physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard School of Medicine, discusses the partnering of the Dana-Farber Cancer Institute with Quest Diagnostics to identify the prevalence of COVID-19 in individuals with a precursor to multiple myeloma through the IMPACT study (Immune Profiling with Antibody-based COVID-19 Testing). She talks about how COVID 19 affects myeloma patients and various racial groups, and how the IMPACT study will play a role in the diagnostic recovery for this population.
Dr. Ghobrial received her MD in 1995 from Cairo University School of Medicine, Egypt. She completed her Internal Medicine training at Wayne State University, Mich., and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, Minn.
She joined Dana-Farber in the field of Waldenstrom’s macroglobulinemia and multiple myeloma in 2005. She is conducting research in the area of homing and migration of B cells and novel therapeutic agents in Waldenstrom’s macroglbulinemia and multiple myeloma.